-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Qj1tuBOCJ3x7vlQyB6yCV7sjHT9NMZVQOAHRaIow10Tt8vF/Dl+O+ci+CeF8yoAz O/HP8FHvok8mxE6Prcg0Sg== 0001179110-07-002843.txt : 20070205 0001179110-07-002843.hdr.sgml : 20070205 20070205202213 ACCESSION NUMBER: 0001179110-07-002843 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20070205 FILED AS OF DATE: 20070205 DATE AS OF CHANGE: 20070205 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNTA PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: 45 HARTWELL AVE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-274-8200 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gollust Keith R CENTRAL INDEX KEY: 0001325712 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 07582278 BUSINESS ADDRESS: BUSINESS PHONE: 781-274-8200 MAIL ADDRESS: STREET 1: C/O SYNTA PHARMACEUTICALS CORP. STREET 2: 45 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 3 1 edgar.xml FORM 3 - X0202 3 2007-02-05 0 0001157601 SYNTA PHARMACEUTICALS CORP SNTA 0001325712 Gollust Keith R C/O SYNTA PHARMACEUTICALS CORP. 45 HARTWELL AVENUE LEXINGTON MA 02421 1 0 0 0 Common Stock 34357 D Common Stock 50000 I By Gollust Trust II Common Stock 915516 I By Wyandanch Partners, L.P. Series A Convertible Preferred Stock Common Stock 300000 I By Wyandanch Partners, L.P. Director Stock Option (Right to Buy) 10.843 2012-07-15 Common Stock 125000 D Director Stock Option (Right to Buy) 10.843 2014-05-27 Common Stock 75000 D Reflects a 1-for-4 reverse stock split effected on February 2, 2007 in connection with the Issuer's initial public offering, pursuant to which the number of shares of Common Stock was divided by 4. These shares are owned directly by the Gollust Trust II, a trust established for the benefit of the Reporting Person's minor children. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These shares are owned directly by Wyandanch Partners, L.P. and indirectly by the Reporting Person as the president and sole stockholder of Gollust Management, Inc., the general partner of Wyandanch Partners, L.P. Upon the closing of the Issuer's initial public offering of Common Stock, each share of Series A Convertible Preferred Stock, plus accrued dividends, will convert into a certain number of shares of Common Stock in accordance with the terms of the Issuer's Restated Certificate of Incorporation, as amended. N/A. The option vested as to 25% of the shares on July 15, 2003 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter and is currently fully vested. Reflects a 1-for-4 reverse stock split effected on February 2, 2007 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of Common Stock underlying the option was divided by 4 and (ii) the exercise price of the option was multiplied by 4. The option vested as to 50% of the shares on May 27, 2004 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter and is currently fully vested. /s/ Ann Margaret Eames, Attorney-in-Fact 2007-02-05 EX-24 2 ex24poakgollust.txt POWER OF ATTORNEY POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Safi R. Bahcall, Ph.D., the President and Chief Executive Officer of Synta Pharmaceuticals Corp. (the "Company"), Keith S. Ehrlich, the Vice President, Finance and Administration, Chief Financial Officer of the Company, and Wendy E. Rieder, the Vice President, Intellectual Property and Legal Affairs, General Counsel of the Company, and Brian Keane, Daniel T. Kajunski, and Ann Margaret Eames of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, forms and authentication documents for EDGAR Filing Access; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents; (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in- fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 29th day of January 2007. /s/ Keith R. Gollust Signature Keith R. Gollust Print Name -----END PRIVACY-ENHANCED MESSAGE-----